Partner Pipeline
partner |
program |
source |
area |
phase 1 |
phase 2 |
phase 3 |
registration |
approved |
|---|---|---|---|---|---|---|---|---|
| Gloria Pharmaceuticals Arcus Biosciences Gilead |
Zimberelimab | OmniRat | Oncology | |||||
| CStone Pharmaceuticals Pfizer |
Sugemalimab | OmniRat | Oncology | |||||
| Janssen | Teclistamab | OmniRat | Oncology | |||||
| Hanall Biopharma Immunovant Harbour BioMed |
Batoclimab | OmniRat | Immunology | |||||
| Genentech | Tiragolumab | OmniRat | Oncology | |||||
| Genmab BioNTech |
GEN1046 | OmniRat | Oncology | |||||
| Merck KGaA | M6223 | OmniRat | Oncology | |||||
| Aptevo Therapeutics | APVO436 | OmniMouse | Oncology | |||||
| Janssen | JNJ-70218902 | OmniRat | Oncology | |||||
| Janssen | JNJ-78306358 | OmniRat | Oncology | |||||
| Genmab | GEN1047 | OmniRat | Oncology | |||||
| CTTQ | S095017 | OmniRat | Oncology | |||||
| Symphogen by Servier | S95018 | OmniRat | Oncology | |||||
| Symphogen by Servier | S95024 | OmniRat | Oncology | |||||
| Symphogen by Servier | S95029 | OmniRat | Oncology | |||||
| AbbVie | ABBV-383 | OmniFlic | Oncology | |||||
| Ancora by AstraZeneca | TNB-486 | OmniFlic | Oncology | |||||
| Amgen | AMG 340 | OmniFlic | Oncology | |||||
| SalubrisBio | SAL003 | OmniRat | Metabolic | |||||
| Curon | CN1 | OmniRat | Oncology | |||||
| Zhilkang Hongyi | Undisclosed | OmniRat | Oncology | |||||
| Boehringer Ingelheim | Undisclosed | OmniChicken | Undisclosed | |||||
| Undisclosed | Undisclosed | OmniRat | Undisclosed | |||||
| Merck KGaA | M9140 | OmniRat | Oncology | |||||
| Genmab BioNTech |
GEN1053 | OmniRat | Oncology | |||||
| Janssen | JNJ-79635322 | OmniRat | Oncology | |||||
| Seagen | SGN-BB228 | OmniRat | Oncology | |||||
| Hanall Biopharma Immunovant |
IMVT-1402 | OmniRat | Immunology | |||||
| Gloria Pharmaceuticals | GLS-012 | OmniRat | Oncology | |||||
| Partner | Gloria Pharmaceuticals Arcus Biosciences Gilead |
|---|---|
| Program | Zimberelimab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | CStone Pharmaceuticals Pfizer |
| Program | Sugemalimab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | Janssen |
| Program | Teclistamab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | Hanall Biopharma Immunovant Harbour BioMed |
| Program | Batoclimab |
| Source | OmniRat |
| Area | Immunology |
| Phase | Registration |
| Partner | Genentech |
| Program | Tiragolumab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 3 |
| Partner | Genmab BioNTech |
| Program | GEN1046 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 2 |
| Partner | Merck KGaA |
| Program | M6223 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 2 |
| Partner | Aptevo Therapeutics |
| Program | APVO436 |
| Source | OmniMouse |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Janssen |
| Program | JNJ-70218902 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Janssen |
| Program | JNJ-78306358 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Genmab |
| Program | GEN1047 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | CTTQ |
| Program | S095017 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen by Servier |
| Program | S95018 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen by Servier |
| Program | S95024 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen by Servier |
| Program | S95029 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | AbbVie |
| Program | ABBV-383 |
| Source | OmniFlic |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Ancora by AstraZeneca |
| Program | TNB-486 |
| Source | OmniFlic |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Amgen |
| Program | AMG 340 |
| Source | OmniFlic |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | SalubrisBio |
| Program | SAL003 |
| Source | OmniRat |
| Area | Metabolic |
| Phase | Phase 1 |
| Partner | Curon |
| Program | CN1 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Zhilkang Hongyi |
| Program | Undisclosed |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Boehringer Ingelheim |
| Program | Undisclosed |
| Source | OmniChicken |
| Area | Undisclosed |
| Phase | Phase 1 |
| Partner | Undisclosed |
| Program | Undisclosed |
| Source | OmniRat |
| Area | Undisclosed |
| Phase | Phase 1 |
| Partner | Merck KGaA |
| Program | M9140 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Genmab BioNTech |
| Program | GEN1053 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Janssen |
| Program | JNJ-79635322 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Seagen |
| Program | SGN-BB228 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Hanall Biopharma Immunovant |
| Program | IMVT-1402 |
| Source | OmniRat |
| Area | Immunology |
| Phase | Phase 1 |
| Partner | Gloria Pharmaceuticals |
| Program | GLS-012 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
Note: Most advanced status for each program shown.